Consumer Reports warns that there are important considerations, especially for older adults, before starting these treatments ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

US rival Eli Lilly last month forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, leading the stock to fall 8%. The shares have since recovered. "We see an ...

The organization that was set to operate a supervised injection site in Charlottetown says it was "disheartened" and "surprised" to learn the province wouldn't be continuing the project as planned.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

This is particularly interesting because mainstream obesity drugs such as Wegovy and Zepbound are administered via injection. An oral tablet could open up new doors for patients who seeking ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...